News
News-Medical.Net on MSN14h
RUNX1C isoform identified as driver of chemoresistance in acute myeloid leukemia
One of the biggest challenges in cancer treatment is that certain cancers reappear after chemotherapy-and an aggressive type ...
One of the biggest challenges in cancer treatment is that certain cancers reappear after chemotherapy—and an aggressive type ...
Artificial intelligence (AI) and socioeconomic factors enhance risk stratification for patients with acute myeloid leukemia (AML) post transplant, aiming to reduce hospital readmissions and disease ...
Amir Fathi, MD, leukemia specialist at Massachusetts General Hospital, discusses the importance of advocacy by both patients ...
Limited (($HCM)) announced an update on their ongoing clinical study. Study Overview: Hutchmed (China) Limited is conducting a ...
TipRanks on MSN4d
Aptose Biosciences Advances Tuspetinib in AML Treatment with Promising Trial Results
The latest update is out from Aptose Biosciences ( (TSE:APS) ).
3."My father recently died of acute myeloid leukemia. Keep in mind, he vehemently refused checkups or doctors' visits for any ...
(Nasdaq: OMER) today announced recent highlights and developments as well as financial results for the second quarter ended June 30, 2025, which include: Net loss for the second quarter of 2025 was ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback